Transjugular Intrahepatic Portosystemic Shunt (TIPS) Market By Device Type (Stents, Accessories), By Application (Portal hypertension, Budd Chiari Syndrome, Others), By End User (Hospitals, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Transjugular Intrahepatic Portosystemic Shunt (TIPS) Market

Transjugular intrahepatic portosystemic shunt (TIPS) is a shunt (tube) placed between the portal vein, which carries blood from intestines/spleen to the liver and the hepatic vein, which carries blood from liver to vena cava and heart. TIPS are performed primarily in patients with cirrhosis in which the scar tissue in the liver causes partial blockage of flow of blood from portal vein through liver to hepatic vein. The blockage in liver increases pressure in the portal vein, which is called portal hypertension. As a result of the increase in pressure, portal blood flow bypasses the liver and is diverted to smaller veins that flow around the abdominal wall, stomach, and esophagus. Portal hypertension can also cause fluid to leak out of the liver into the abdomen or right chest around the lung. TIPS procedure is performed through small incision in right side of the neck through internal Jugular vein, and the largest vein in the neck. Under x-ray guidance, a stent (metal tube/shunt) is placed from the hepatic vein to the portal vein.

Surge in technological advances in transjugular intrahepatic portosystemic shunt devices propels growth of the market. In addition, the medical device sector has opened new approaches and collaborations in the industry to respond to urgent needs of health problems. According to the American Association for study of Liver Diseases in 2022, its mission is to advance the science and practice of hepatology, and promoting liver health and optimal care of patients with liver diseases. Thus, rise in initiatives taken by private healthcare organizations for prevention of liver diseases significantly drives growth of the market. According to the National Center for Disease Control and Prevention in 2020, it was estimated that mortality rate of Cirrhosis in Mexico was 33.4% and 753 deaths. Moreover, thrombosis is the major cause of hepatic vein obstruction. Thus, rise in number of cases of cirrhosis lead to increase in demand for transjugular intrahepatic portosystemic shunt (TIPS) escalating growth of the market.

Increase in government support for management of liver diseases and surge in demand for effective prevention treatment are the major factors that drive growth of the global transjugular intrahepatic portosystemic shunt (TIPS) market. In addition, key players, such as Boston Scientific Corporation, Cook Medical, and Angiodynamics contribute toward the growth of transjugular intrahepatic portosystemic shunt industry. Furthermore, rise in number of product approvals is expected to provide remunerative opportunities for expansion of the global market during the forecast period. Sedentary lifestyle makes people susceptible to having many disorders such as portal vein thrombosis, and cirrhosis. This disease is associated with high hospitalization rate and substantial cost due to frequent use of this devices. Thus, increase in number of surgeries, owing to rise in cases of chronic liver diseases is expected to increase adoption of transjugular intrahepatic portosystemic shunt (TIPS) products and increase growth of the market.

However, high costs of transjugular intrahepatic portosystemic shunt (TIPS) procedure, limited availability of funds, and dearth of skilled professionals are the factors projected to impede the market growth. Presently, there is an increase in awareness regarding health among people, which, in turn, compels them to maintain their health condition and leads to rise in use of transjugular intrahepatic portsystemic shunt by health professionals in surgical centers. This has encouraged many key players to enter emerging markets, thus offering lucrative growth opportunities in the TIPS market.

Moreover, increase in number of medical devices manufacturing plants surge demand for use of transjugular intrahepatic portosystemic shunt devices, creating an opportunity for manufacturers to tap and capitalize on the market. The transjugular intrahepatic portosystemic shunt (TIPS) market size is studied by device type, which is divided into stents and accessories and by application, which is fragmented into portal hypertension, Budd-Chiari Syndrome, and others. By end user, it is categorized into hospitals, specialty clinics, and others. By region, the transjugular intrahepatic portosystemic shunt industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By device type, the stents segment dominated the global market in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to increase in R&D activities in the medical device industry, rise in clinical efficiency of TIPS in treatment of portal vein thrombosis, and hepatopulmonary syndrome. By application, the portal hypertension segment dominated the global market in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to increase in number of cases of portal hypertension. By end user, it is categorized into hospitals, specialty centers, and others. The hospitals segment acquired the largest share in 2021, and is expected to remain dominant throughout the forecast period. This is attributed to increase in number of liver disease patients and surge in number of hospital admissions.

By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. By region, North America accounted for the largest transjugular intrahepatic portosystemic shunt (TIPS) market share in 2021, and is expected to remain dominant throughout the forecast period. This was attributed to presence of giant medical device companies in countries such as the U.S. In addition, increase in frequency of major medical device companies and their R&D activities drive demand for transjugular intrahepatic portosystemic shunt in the region during the forecast period.

KEY FINDINGS OF THE STUDY

The study provides an in-depth transjugular intrahepatic portosystemic shunt (TIPS) market analysis, and the future estimations to elucidate imminent investment pockets & current transjugular intrahepatic portosystemic shunt (TIPS) market trends.

By device type, the stents segment held largest market share in 2021, and is expected to remain dominant throughout the transjugular intrahepatic portosystemic shunt (TIPS) market forecast.

By application, the portal hypertension segment held largest market share in 2021, and is expected to remain dominant throughout the forecast period

By end user, the hospitals segment dominates the global market in 2021, and is anticipated to continue this trend during the forecast period.

By region, Asia-Pacific is expected to experience growth at the highest rate during the forecast period.

Overview

The global transjugular intrahepatic portosystemic shunt (TIPS) market was valued at $93,370.5 thousand in 2021, and is projected to reach $127,937.57 thousand by 2031, registering a CAGR of 3.2% from 2022 to 2031.

Transjugular intrahepatic portosystemic shunt (TIPS) is an artificial passage that allows fluid to move from one part of the liver to another. It connects veins that carry blood from gastrointestinal tract and intra-abdominal organs to liver and veins from liver to right part of the heart. In this procedure a small metal device, which is called stent is placed to keep connection of vein and liver. Doctor inserts a catheter, which is a flexible tube through skin into the vein of neck. This vein is known as jugular vein. Transjugular intrahepatic portosystemic shunt reduces internal bleeding in stomach and may also reduce accumulation of fluid in the abdomen. This procedure is done by interventional radiologists using x-ray guidance.

Growth of the transjugular intrahepatic portosystemic shunt market is supported by rise in cases of portal hypertension and increase in adoption of transjugular intrahepatic portosystemic shunts to minimize barriers. In addition, constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) make individuals more susceptible to liver failure. In addition, a number of factors such as a large number of technological advancements in transjugular intrahepatic portosystemic shunt and rise in emphasis on early intervention and primary prevention of liver related disorders are responsible for driving the market growth. Moreover, rise in demand and adoption of products such as stent, catheters, sheath and guidewires and launch of transjugular intrahepatic portosystemic shunt devices by large number of key players are the major factors driving the market growth. Furthermore, according to the World Health Organization, in 2019, approximately 1.28 billion people suffered from hypertension, which is the main cause of death. Thus, rise in number of cases of people suffering from hypertension leads to increase in use of transjugular intrahepatic portosystemic shunt drives growth of the market. Moreover, surge in incidences of emergency surgeries and growing adoption of vascular devices propel growth of the transjugular intrahepatic portosystemic shunt (TIPS) market. Liver disease causes damage of liver and leads to cirrhosis.

According to the report by the Gov.UK in 2021, it was estimated that there were approximately 10,127 deaths due to liver disease in England and it increased as compared to 2019. Moreover, the number of rate of people died in England due to liver disease was 20.6 per 100,000 population with ages under 75. In addition, according to the National Center for Disease Control and Prevention in 2020, it was estimated that mortality rate of cirrhosis was 7.0% in New York, with approximately 1,672 number of deaths. Thus, rising number of cases suffering from cirrhosis led to increase in usage of transjugular intrahepatic portosystemic shunt devices for treatment that significantly drive growth of the market. For instance, in 2019, it was estimated that approximately 820,000 people died due to cirrhosis and hepatocellular carcinoma globally. Thus, rising number of cases of cirrhosis leads to higher demand among people. Hence, usage of transjugular intrahepatic portosystemic shunt (TIPS) fuel the growth of the market. Moreover, development of medical device industries and improvement in healthcare spending are anticipated to drive growth of the transjugular intrahepatic portosystemic shunt (TIPS) market. 

For instance, in June 2022, Boston Scientific Corporation entered into definitive agreement with Synergy Innovation Co. Ltd. to purchase its majority stake of M.I. Tech Co., Ltd., Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. M.I Tech Co. Ltd is the creator of the HANAROSTENT technology, a non-vascular self-expanding metal stent. Non-vascular gastrointestinal stents are used to help treat occlusions in various areas of gastrointestinal tract. Thus, rising number of strategies such as agreement and acquisitions among key players drive growth of the market.

Furthermore, rise in geriatric population and increase in burden of liver diseases lead to rise in awareness regarding transjugular intrahepatic portosystemic shunt treatment among people, which drive growth of the market. Moreover, according to the American Liver foundation in 2020, it was estimated that approximately 51,642 adults in the U.S died due to liver disease and 4.5 million adults have been diagnosed with the disease. Moreover, The American Liver Foundation is the largest non-profit organization focused solely on promoting liver health and disease prevention.

The American Liver Foundation fights against liver disease by funding scientific research and support programs for patients with liver disease and their families as well as creating public awareness by launching various awareness campaigns about liver wellness and disease prevention. Thus, rising number of cases of liver diseases in the U.S and other countries and initiatives taken by private and government healthcare organizations to prevent liver disorders drive growth of the global market. Moreover, increase in healthcare expenditure in emerging economies and high demand for minimally invasive procedures are expected to provide new opportunities for market players. However, lack of awareness in developing regions is anticipated to hamper the market growth.

The transjugular intrahepatic portosystemic shunt (TIPS) market is studied by device type, which is divided into stents and accessories and by application, which is fragmented into portal hypertension, Budd-Chiari Syndrome, and others. By end user, it is categorized into hospitals, specialty clinics, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key players mentioned in the report are Boston Scientific Corporation, W.L Gore Associated Ltd, Angiodynamics, and Neuromedex GmbH, and Cook Medical, Becton Dickinson and Company, and Terumo Medical Corporation.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the transjugular intrahepatic portosystemic shunt (tips) market analysis from 2021 to 2031 to identify the prevailing transjugular intrahepatic portosystemic shunt (tips) market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the transjugular intrahepatic portosystemic shunt (tips) market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global transjugular intrahepatic portosystemic shunt (tips) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Company 1

Scope of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Stents

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Accessories

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Portal hypertension

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Budd Chiari Syndrome

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Specialty Clinics

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Others

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Device Type

7.2.3 North America Market size and forecast, by Application

7.2.4 North America Market size and forecast, by End User

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Device Type

7.2.5.1.2 Market size and forecast, by Application

7.2.5.1.3 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Device Type

7.2.5.2.2 Market size and forecast, by Application

7.2.5.2.3 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Device Type

7.2.5.3.2 Market size and forecast, by Application

7.2.5.3.3 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Device Type

7.3.3 Europe Market size and forecast, by Application

7.3.4 Europe Market size and forecast, by End User

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Device Type

7.3.5.1.2 Market size and forecast, by Application

7.3.5.1.3 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Device Type

7.3.5.2.2 Market size and forecast, by Application

7.3.5.2.3 Market size and forecast, by End User

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Device Type

7.3.5.3.2 Market size and forecast, by Application

7.3.5.3.3 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Device Type

7.3.5.4.2 Market size and forecast, by Application

7.3.5.4.3 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Device Type

7.3.5.5.2 Market size and forecast, by Application

7.3.5.5.3 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Device Type

7.3.5.6.2 Market size and forecast, by Application

7.3.5.6.3 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Device Type

7.4.3 Asia-Pacific Market size and forecast, by Application

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Device Type

7.4.5.1.2 Market size and forecast, by Application

7.4.5.1.3 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Device Type

7.4.5.2.2 Market size and forecast, by Application

7.4.5.2.3 Market size and forecast, by End User

7.4.5.3 Australia

7.4.5.3.1 Market size and forecast, by Device Type

7.4.5.3.2 Market size and forecast, by Application

7.4.5.3.3 Market size and forecast, by End User

7.4.5.4 India

7.4.5.4.1 Market size and forecast, by Device Type

7.4.5.4.2 Market size and forecast, by Application

7.4.5.4.3 Market size and forecast, by End User

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Device Type

7.4.5.5.2 Market size and forecast, by Application

7.4.5.5.3 Market size and forecast, by End User

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Device Type

7.4.5.6.2 Market size and forecast, by Application

7.4.5.6.3 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Device Type

7.5.3 LAMEA Market size and forecast, by Application

7.5.4 LAMEA Market size and forecast, by End User

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Device Type

7.5.5.1.2 Market size and forecast, by Application

7.5.5.1.3 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Device Type

7.5.5.2.2 Market size and forecast, by Application

7.5.5.2.3 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Device Type

7.5.5.3.2 Market size and forecast, by Application

7.5.5.3.3 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Device Type

7.5.5.4.2 Market size and forecast, by Application

7.5.5.4.3 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Boston Scientific Corporation

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 W. L. Gore & Associates, Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Cook

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 BD

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 AngioDynamics Inc.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Neuromedex GmbH

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Terumo Medical Corporation

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Company 8

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Company 9

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Company 10

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 2. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR STENTS, BY REGION, 2021-2031 ($THOUSAND)

TABLE 3. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR STENTS, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 4. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR ACCESSORIES, BY REGION, 2021-2031 ($THOUSAND)

TABLE 5. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR ACCESSORIES, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 6. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 7. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR PORTAL HYPERTENSION, BY REGION, 2021-2031 ($THOUSAND)

TABLE 8. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR PORTAL HYPERTENSION, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 9. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR BUDD CHIARI SYNDROME, BY REGION, 2021-2031 ($THOUSAND)

TABLE 10. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR BUDD CHIARI SYNDROME, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 11. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR OTHERS, BY REGION, 2021-2031 ($THOUSAND)

TABLE 12. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 13. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 14. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($THOUSAND)

TABLE 15. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 16. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR SPECIALTY CLINICS, BY REGION, 2021-2031 ($THOUSAND)

TABLE 17. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 18. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, FOR OTHERS, BY REGION, 2021-2031 ($THOUSAND)

TABLE 19. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 20. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY REGION, 2021-2031 ($THOUSAND)

TABLE 21. NORTH AMERICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 22. NORTH AMERICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 23. NORTH AMERICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 24. NORTH AMERICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 25. U.S. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 26. U.S. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 27. U.S. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 28. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 29. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 30. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 31. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 32. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 33. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 34. EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 35. EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 36. EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 37. EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 38. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 39. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 40. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 41. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 42. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 43. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 44. UK TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 45. UK TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 46. UK TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 47. ITALY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 48. ITALY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 49. ITALY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 50. SPAIN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 51. SPAIN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 52. SPAIN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 53. REST OF EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 54. REST OF EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 55. REST OF EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 56. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 57. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 58. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 59. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 60. JAPAN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 61. JAPAN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 62. JAPAN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 63. CHINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 64. CHINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 65. CHINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 66. AUSTRALIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 67. AUSTRALIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 68. AUSTRALIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 69. INDIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 70. INDIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 71. INDIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 72. SOUTH KOREA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 73. SOUTH KOREA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 74. SOUTH KOREA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 75. REST OF ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 76. REST OF ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 77. REST OF ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 78. LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 79. LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 80. LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 81. LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY COUNTRY, 2021-2031 ($THOUSAND)

TABLE 82. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 83. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 84. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 85. SAUDI ARABIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 86. SAUDI ARABIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 87. SAUDI ARABIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 88. SOUTH AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 89. SOUTH AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 90. SOUTH AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 91. REST OF LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE, 2021-2031 ($THOUSAND)

TABLE 92. REST OF LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION, 2021-2031 ($THOUSAND)

TABLE 93. REST OF LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER, 2021-2031 ($THOUSAND)

TABLE 94.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT

TABLE 95.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS

TABLE 96.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO

TABLE 97.BOSTON SCIENTIFIC CORPORATION: NET SALES,

TABLE 98.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES

TABLE 99.W. L. GORE & ASSOCIATES, INC. : COMPANY SNAPSHOT

TABLE 100.W. L. GORE & ASSOCIATES, INC. : OPERATING SEGMENTS

TABLE 101.W. L. GORE & ASSOCIATES, INC. : PRODUCT PORTFOLIO

TABLE 102.W. L. GORE & ASSOCIATES, INC. : NET SALES,

TABLE 103.W. L. GORE & ASSOCIATES, INC. : KEY STRATERGIES

TABLE 104.COOK: COMPANY SNAPSHOT

TABLE 105.COOK: OPERATING SEGMENTS

TABLE 106.COOK: PRODUCT PORTFOLIO

TABLE 107.COOK: NET SALES,

TABLE 108.COOK: KEY STRATERGIES

TABLE 109.BD: COMPANY SNAPSHOT

TABLE 110.BD: OPERATING SEGMENTS

TABLE 111.BD: PRODUCT PORTFOLIO

TABLE 112.BD: NET SALES,

TABLE 113.BD: KEY STRATERGIES

TABLE 114.ANGIODYNAMICS INC.: COMPANY SNAPSHOT

TABLE 115.ANGIODYNAMICS INC.: OPERATING SEGMENTS

TABLE 116.ANGIODYNAMICS INC.: PRODUCT PORTFOLIO

TABLE 117.ANGIODYNAMICS INC.: NET SALES,

TABLE 118.ANGIODYNAMICS INC.: KEY STRATERGIES

TABLE 119.NEUROMEDEX GMBH: COMPANY SNAPSHOT

TABLE 120.NEUROMEDEX GMBH: OPERATING SEGMENTS

TABLE 121.NEUROMEDEX GMBH: PRODUCT PORTFOLIO

TABLE 122.NEUROMEDEX GMBH: NET SALES,

TABLE 123.NEUROMEDEX GMBH: KEY STRATERGIES

TABLE 124.TERUMO MEDICAL CORPORATION: COMPANY SNAPSHOT

TABLE 125.TERUMO MEDICAL CORPORATION: OPERATING SEGMENTS

TABLE 126.TERUMO MEDICAL CORPORATION: PRODUCT PORTFOLIO

TABLE 127.TERUMO MEDICAL CORPORATION: NET SALES,

TABLE 128.TERUMO MEDICAL CORPORATION: KEY STRATERGIES

TABLE 129.COMPANY 8: COMPANY SNAPSHOT

TABLE 130.COMPANY 8: OPERATING SEGMENTS

TABLE 131.COMPANY 8: PRODUCT PORTFOLIO

TABLE 132.COMPANY 8: NET SALES,

TABLE 133.COMPANY 8: KEY STRATERGIES

TABLE 134.COMPANY 9: COMPANY SNAPSHOT

TABLE 135.COMPANY 9: OPERATING SEGMENTS

TABLE 136.COMPANY 9: PRODUCT PORTFOLIO

TABLE 137.COMPANY 9: NET SALES,

TABLE 138.COMPANY 9: KEY STRATERGIES

TABLE 139.COMPANY 10: COMPANY SNAPSHOT

TABLE 140.COMPANY 10: OPERATING SEGMENTS

TABLE 141.COMPANY 10: PRODUCT PORTFOLIO

TABLE 142.COMPANY 10: NET SALES,

TABLE 143.COMPANY 10: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET SEGMENTATION

FIGURE 2.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031

FIGURE 3.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,BY DEVICE TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF STENTS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ACCESSORIES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 15.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,BY APPLICATION,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PORTAL HYPERTENSION TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BUDD CHIARI SYNDROME TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 19.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,BY END USER,2021(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITALS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SPECIALTY CLINICS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031(%)

FIGURE 23.TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET BY REGION,2021

FIGURE 24.U.S. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 25.CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 26.MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 27.GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 28.FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 29.UK TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 30.ITALY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 31.SPAIN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 32.REST OF EUROPE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 33.JAPAN TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 34.CHINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 35.AUSTRALIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 36.INDIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 37.SOUTH KOREA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 38.REST OF ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 39.BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 40.SAUDI ARABIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 41.SOUTH AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 42.REST OF LAMEA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET,2021-2031($THOUSAND)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47.COMPETITIVE DASHBOARD

FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 49.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($THOUSAND)

FIGURE 50.W. L. GORE & ASSOCIATES, INC. .: NET SALES ,($THOUSAND)

FIGURE 51.COOK.: NET SALES ,($THOUSAND)

FIGURE 52.BD.: NET SALES ,($THOUSAND)

FIGURE 53.ANGIODYNAMICS INC..: NET SALES ,($THOUSAND)

FIGURE 54.NEUROMEDEX GMBH.: NET SALES ,($THOUSAND)

FIGURE 55.TERUMO MEDICAL CORPORATION.: NET SALES ,($THOUSAND)

FIGURE 56.COMPANY 8.: NET SALES ,($THOUSAND)

FIGURE 57.COMPANY 9.: NET SALES ,($THOUSAND)

FIGURE 58.COMPANY 10.: NET SALES ,($THOUSAND